The first retrospective study evaluated the role of CRP in a series of 56 patients with different tumors (28.6% NSCLC) treated with anti PD-1 and anti PD-L1 treatment, and established the optimal cut-off value in 10 mg/mL. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.